4.5 Article

SINGLE-DOSE PHARMACOKINETICS AND TOLERABILITY OF DAPTOMYCIN 8 TO 10 MG/KG IN CHILDREN AGED 2 TO 6 YEARS WITH SUSPECTED OR PROVED GRAM-POSITIVE INFECTIONS

Journal

PEDIATRIC INFECTIOUS DISEASE JOURNAL
Volume 30, Issue 8, Pages 712-714

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0b013e31820fc8e1

Keywords

daptomycin; pediatric; pharmacokinetics

Funding

  1. Targanta Therapeutics
  2. Roche
  3. AstraZeneca
  4. Bristol-Myers Squibb
  5. Johnson and Johnson
  6. Pfizer

Ask authors/readers for more resources

A pharmacokinetic analysis was performed for single intravenous doses of daptomycin 8 or 10 mg/kg in subjects aged 2 to 6 years. Proportional increases in maximum plasma concentration (68.4 mu g/mL, 79.2 mu g/mL) and area under the curve (429.1 mu g.h/mL, 549.7 mu g.h/mL) were observed for each dose cohort, respectively. Half-life, clearance, and distribution volume were similar between groups. Both doses were well tolerated.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available